Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations

被引:301
作者
Hu, Kaili [1 ]
Li, Jingwei [1 ]
Shen, Yehong [1 ]
Lu, Wei [1 ]
Gao, Xiaoling [1 ]
Zhang, Qizhi [1 ]
Jiang, Xinguo [1 ]
机构
[1] Fudan Univ, Sch Pharm, Dept Pharmaceut, Shanghai 200032, Peoples R China
关键词
Lactoferrin; Blood-brain barrier (BBB); Coumarin-6; Biodegradable nanoparticle; Brain delivery; STRIATAL TYROSINE-HYDROXYLASE; CENTRAL-NERVOUS-SYSTEM; NONVIRAL GENE-THERAPY; DRUG-DELIVERY; EXPERIMENTAL PARKINSONISM; ENDOTHELIAL-CELLS; MOTOR IMPAIRMENT; MOUSE-BRAIN; BARRIER; RECEPTOR;
D O I
10.1016/j.jconrel.2008.10.016
中图分类号
O6 [化学];
学科分类号
070301 [无机化学];
摘要
The lactoferrin (Lf) conjugated poly (ethyleneglycol)-poly (lactide) nanoparticle (Lf-NP) was constructed in this paper as a novel biodegradable brain drug delivery system with evaluation of its in vitro and in vivo delivery properties. Lf was thiolated and conjugated to the distal maleimide functions surrounding on the pegylated nanoparticles to form the Lf-NP. The existence of Lf on the surface of Lf-NP was verified by TEM observation and XPS analysis. The Lf ELISA results confirmed the biorecognitive activity of Lf after the coupling procedure and suggested the average number of Lf conjugated on each nanoparticle was around 55. a fluorescent probe, coumarin-6 was incorporated into To evaluate the brain delivery properties of the Lf-NP, it. The uptake of Lf-NP by bEnd.3 cells was shown significantly higher than that of unconjugated nanoparticle (NP). Following an intravenous administration, a near 3 folds of coumarin-6 were found in the mice brain carried by Lf-NP compared to that carried by NP. Cell viability experiment results confirmed good safety of the biodegradable Lf-NP. The significant in vitro and in vivo results suggest that Lf-NP is a promising brain drug delivery system with low toxicity. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 42 条
[1]
Amphiphilic block copolymers for drug delivery [J].
Adams, ML ;
Lavasanifar, A ;
Kwon, GS .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (07) :1343-1355
[2]
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities [J].
Begley, DJ .
PHARMACOLOGY & THERAPEUTICS, 2004, 104 (01) :29-45
[3]
Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells [J].
Brown, Rachel C. ;
Morris, Andrew P. ;
O'Neil, Roger G. .
BRAIN RESEARCH, 2007, 1130 (01) :17-30
[4]
Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery [J].
Calvo, P ;
Gouritin, B ;
Chacun, H ;
Desmaële, D ;
D'Angelo, J ;
Noel, JP ;
Georgin, D ;
Fattal, E ;
Andreux, JP ;
Couvreur, P .
PHARMACEUTICAL RESEARCH, 2001, 18 (08) :1157-1166
[5]
Characterization of nanoparticle uptake by endothelial cells [J].
Davda, J ;
Labhasetwar, V .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 233 (1-2) :51-59
[6]
Strategies to improve drug delivery across the blood-brain barrier [J].
de Boer, Albertus G. ;
Gaillard, Pieter J. .
CLINICAL PHARMACOKINETICS, 2007, 46 (07) :553-576
[7]
The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent [J].
Desai, MP ;
Labhasetwar, V ;
Walter, E ;
Levy, RJ ;
Amidon, GL .
PHARMACEUTICAL RESEARCH, 1997, 14 (11) :1568-1573
[8]
Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs [J].
Dong, YC ;
Feng, SS .
BIOMATERIALS, 2004, 25 (14) :2843-2849
[9]
TISSUE SULFHYDRYL GROUPS [J].
ELLMAN, GL .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1959, 82 (01) :70-77
[10]
EXPRESSION OF LACTOFERRIN RECEPTORS IS INCREASED IN THE MESENCEPHALON OF PATIENTS WITH PARKINSON DISEASE [J].
FAUCHEUX, BA ;
NILLESSE, N ;
DAMIER, P ;
SPIK, G ;
MOUATTPRIGENT, A ;
PIERCE, A ;
LEVEUGLE, B ;
KUBIS, N ;
HAUW, JJ ;
AGID, Y ;
HIRSCH, EC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (21) :9603-9607